Annals of Colorectal Research

Published by: Kowsar

Aspirin for the Primary Prophylaxis of Colorectal Cancer

Kamran B Lankarani 1 , *
Author Information
1 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Annals of Colorectal Research: December 1, 2013, 1 (3); 77-80
  • Published Online: October 30, 2013
  • Article Type: Review Article
  • Received: November 19, 2013
  • Accepted: November 20, 2013
  • DOI: 10.17795/acr-16264

To Cite: B Lankarani K. Aspirin for the Primary Prophylaxis of Colorectal Cancer, Ann Colorectal Res. 2013 ; 1(3):77-80. doi: 10.17795/acr-16264.

Abstract
Copyright © 2013, Colorectal Research Center and Health Policy Research Center of Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisitions
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Lankarani KB. Why Colorectal Diseases are Important? Ann Colorectal Res. 2013; 1(1): 1-2[DOI]
  • 2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. N Eng J Med. 2003; 348(10): 891-9[DOI][PubMed]
  • 3. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369(9573): 1603-13[DOI][PubMed]
  • 4. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 376(9754): 1741-50[DOI]
  • 5. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011; 378(9809): 2081-7[DOI][PubMed]
  • 6. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294(1): 47-55[DOI][PubMed]
  • 7. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998; 128(9): 713-20[PubMed]
  • 8. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012; 9(5): 259-67[DOI][PubMed]
  • 9. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377(9759): 31-41[DOI][PubMed]
  • 10. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011; 106(4): 731-6[DOI][PubMed]
  • 11. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005; 54(11): 1573-8[DOI][PubMed]
  • 12. Herfarth H. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis. Dig Dis. 2012; 30 Suppl 2: 55-9[DOI][PubMed]
  • 13. Lindgren S. The variable risk of colorectal cancer in patients with inflammatory bowel disease. Eur J Intern Med. 2005; 16(3): 139-40[DOI][PubMed]
  • 14. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376(9754): 1741-50[DOI][PubMed]
  • 15. Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One. 2013; 8(7)[DOI][PubMed]
  • 16. Wu C, Goldberg RM. Colorectal cancer in 2012: Revisiting landmark trials and identifying new therapies. Nat Rev Clin Oncol. 2013; 10(2): 71-2[DOI][PubMed]
  • 17. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-Dose Aspirin for the Prevention of Atherothrombosis. N Eng J Med. 2005; 353(22): 2373-83[DOI][PubMed]
  • 18. Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Cl Ga. 2011; 25(4–5): 461-72[DOI]
  • 19. Patrono Carlo, Patrignani Paola, guez Luis AGarc. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001; 108(1): 7-13[DOI]
  • 20. Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol. 2013; 85(2): 234-44[DOI][PubMed]
  • 21. Babbar N, Gerner EW, Casero RA, Jr. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J. 2006; 394: 317-24[PubMed]
  • 22. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-60[DOI][PubMed]
  • 23. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998; 351(9098): 233-41[DOI]
  • 24. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295(3): 306-13[DOI]
  • 25. Ridker PaulM, Cook NancyR, Lee I-Min, Gordon David, Gaziano JMichael, Manson JoAnnE, et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Eng J Med. 2005; 352(13): 1293-1304[DOI][PubMed]
  • 26. Roncaglioni MariaCarla. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice. Lancet. 2001; 357(9250): 89-95[PubMed]
  • 27. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011; 107(12): 1796-801[DOI][PubMed]
  • 28. Erratum for Bartolucci et al. “Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin” Am J Cardiol 2011;107:1796–1801. Am J Cardiol. 2011; 108(4): 615[DOI]
  • 29. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012; 172(3): 209-16[DOI][PubMed]
  • 30. Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med. 2012; 125(6): 560-7[DOI][PubMed]
  • 31. Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry. 1997; 62(3): 269-72[PubMed]
  • 32. Devine ME, Rands G. Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis. Int J Geriatr Psych. 2003; 18(5): 425-31[DOI]
  • 33. Henderson N, Smith T. Aspirin for the next generation. Ecancermedicalscience. 2013; 7: 300[PubMed]
  • 34. Price JF, Stewart MC, Deary IJ, Murray GD, Sandercock P, Butcher I, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ. 2008; 337[PubMed]
  • 35. Sivarasan N, Smith G. Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J Dig Dis. 2013; 14(5): 222-30[DOI][PubMed]
  • 36. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2012; 131(2): 581-7[DOI][PubMed]
  • 37. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer. 2013; 119(8): 1562-9[DOI][PubMed]
  • 38. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM, et al. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013; 132(5): 1146-55[DOI][PubMed]
  • 39. Oh SW, Myung SK, Park JY, Lee CM, Kwon HT, Korean Meta-analysis Study Group. Aspirin use and risk for lung cancer: a meta-analysis. Ann Oncol. 2011; 22(11): 2456-65[DOI][PubMed]
  • 40. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin. BMJ. 2000; 321(7270): 1183-7
  • 41. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52(5): 563-71[PubMed]
  • 42. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in. Am J Cardiol. 2005; 95(10): 1218-22[PubMed]
  • 43. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002; 55(2): 157-63[PubMed]
  • 44. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006; 4: 22[PubMed]
  • 45. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 150(6): 396-404[PubMed]
  • 46. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and. Lancet. 2012; 379(9826): 1602-12[PubMed]
  • 47. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011; 162(1): 115-2400[DOI][PubMed]
  • 48. Sandler RS. Aspirin Should Not Be Promoted for Colon Cancer Prevention: Counterpoint. Cancer Epidemiol Biomarkers Prev. 2008; 17(7): 1562-3[DOI][PubMed]
  • 49. Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry. Cancer Epidemiol. 2011; 35(5)-7[DOI][PubMed]
  • 50. U. S. Preventive Services Task Force . Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007; 146(5): 361-4[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments